Cargando…

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease

INTRODUCTION: The benefit of adding an immunomodulator to vedolizumab and ustekinumab remains unclear and may compromise the safety of these biologics. We evaluated the prevalence and predictors of immunomodulator use with vedolizumab or ustekinumab in patients with inflammatory bowel disease in a l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lutz, Megan, Caldera, Freddy, Schroeder, Katie, Gazis, Derek, Crawford, Julie M., Long, Millie D., Barnes, Edward L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684180/ https://www.ncbi.nlm.nih.gov/pubmed/37450671 http://dx.doi.org/10.14309/ctg.0000000000000620

Ejemplares similares

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Is Vedolizumab Truly Gut Selective? It May Not Affect the Immunogenicity of Vaccines in Patients With Inflammatory Bowel Disease
por: Lee, Alexander S, et al.
Publicado: (2020)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

COVID-19 vaccination in adults with inflammatory bowel disease
por: Lutz, Megan, et al.
Publicado: (2023)

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
por: Mitrova, Katarina, et al.
Publicado: (2021)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Adalimumab/ustekinumab/vedolizumab: COVID-19 infection: 7 case reports
Publicado: (2022)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
por: Jeffrey, Angus W., et al.
Publicado: (2023)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
por: Gara, Sirisha K, et al.
Publicado: (2023)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
por: Click, Benjamin, et al.
Publicado: (2022)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience
por: Erdoğan, Çağdaş, et al.
Publicado: (2022)

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
por: Abraham, Bincy P., et al.
Publicado: (2023)

Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD
por: Click, Benjamin, et al.
Publicado: (2021)

Cholinergic immunomodulation in inflammatory bowel diseases
por: Serafini, Michele A., et al.
Publicado: (2021)

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
por: Vu, Michelle, et al.
Publicado: (2023)

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan
por: Aoki, Yasuhiro, et al.
Publicado: (2022)

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
por: Yarur, Andres J., et al.
Publicado: (2020)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease
por: Singh, Harmanjit, et al.
Publicado: (2016)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dumgkp1hlkp9bhicht2gbcmphh